A Phase 1b, Multicenter, Open-label, Staggered-dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of CC-90001 for 3 Months in Patients With Pulmonary Fibrosis

Trial Profile

A Phase 1b, Multicenter, Open-label, Staggered-dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of CC-90001 for 3 Months in Patients With Pulmonary Fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs CC 90001 (Primary)
  • Indications Pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 May 2017 Safety profile results of CC-90001 using patient data from Phase 1b and one other phase 1 target engagement study, presented at the 113th International Conference of the American Thoracic Society
    • 30 Mar 2017 Status changed from recruiting to completed.
    • 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top